- For Print
- May 15, 2024
Listed Company Name: 缅北禁地.
Representative: Haruo Naito
Representative Corporate Officer and CEO
Securities Code: 4523
Stock Exchange Listings: Prime Market of the Tokyo Stock Exchange
Inquiries: Sayoko Sasaki
Vice President, Corporate Communications
Phone +81-3-3817-5120
缅北禁地. (“the Company”) resolved at its Board of Directors meeting held on May 15, 2024, to appoint a new Representative Corporate Officer, effective June 14, 2024 as described below.
1. Reason for Change
The Company is dedicated to maximizing our contribution to global patients and building a dementia ecosystem through our efforts with the Alzheimer's Disease treatment LEQEMBI. To realize our Corporate Concept and achieve sustainable growth, the corporate officer responsible for leading the maximization of corporate value based on this strategy will be assigned as a representative corporate officer.
2. Appointment of New Representative Corporate Officer (effective June 14, 2024)
(Newly Appointed Representative Corporate Officer)
| New Job Title | Name | Current Job Title |
|---|---|---|
| Representative Corporate Officer and Executive Vice President | Keisuke Naito |
Senior Vice President Chief Strategy and Planning Officer Chief Ecosystem Officer Global Alzheimer's Disease Officer |
3. Career Summary of Newly Appointed Representative Corporate Officer
| Name: | Keisuke Naito | |
|---|---|---|
| Date of Birth: | August 18, 1988 | |
| October 2013 | Joined the Company | |
| February 2019 | Head of Dementia Total Inclusive Ecosystem HQs | |
| June 2019 | Vice President | |
| June 2019 | Chief Digital Officer | |
| June 2019 | Assigned to Dementia Total Inclusive Ecosystem | |
| January 2020 | President, Dementia Total Inclusive Ecosystem HQs | |
| October 2020 | Head of Consumer Experience Transformation HQs | |
| October 2020 | Deputy President, Eisai Japan | |
| June 2021 | Chief Ecosystem Officer (Current) | |
| April 2022 | Head of Global IT Management HQs | |
| June 2023 | Senior Vice President (Current) | |
| June 2023 | Chief Strategy & Planning Officer (Current) | |
| August 2023 | Global Alzheimer's Disease Officer (Current) |
Number of shares held: 970 shares (as of March 31, 2024)
4. Scheduled Transfer Date
June 14, 2024